Latent autoimmune diabetes in adults (LADA) is a form of autoimmune diabetes that develops slowly, typically after age 30, and is frequently misdiagnosed as type 2 diabetes. Unlike classic type 1 diabetes, where insulin-producing cells are destroyed rapidly, LADA progresses over months to years, meaning people can initially manage their blood sugar without insulin. An estimated 2% to 20% of adults diagnosed with type 2 diabetes may actually have LADA, with many studies finding the rate around 4% to 5%.
How LADA Differs From Type 1 and Type 2
LADA sits between type 1 and type 2 diabetes in almost every measurable way. Like type 1, it’s driven by the immune system attacking the insulin-producing beta cells in the pancreas. But like type 2, it shows up later in life and progresses slowly enough that people don’t need insulin right away. The formal diagnostic criteria reflect this hybrid nature: age 30 or older at diagnosis, at least one positive autoantibody test, and no insulin requirement for the first six months.
The key distinction from type 2 diabetes is autoimmunity. People with LADA have immune cells, particularly certain T cells and B cells, that infiltrate the pancreas and gradually destroy beta cells. This process involves several types of immune cells, including macrophages that produce inflammatory signals, triggering a chain reaction that leads to beta cell death. The destruction is real and progressive, but it happens on a slower timeline than in childhood-onset type 1 diabetes.
People with LADA retain more functioning beta cells at the time of diagnosis compared to those with classic type 1 diabetes. This is why blood sugar can initially be controlled with diet, exercise, or oral medications. But over the following years, insulin production steadily declines. Studies tracking C-peptide levels (a marker of how much insulin the body is still making) show a rapid decline over three to six years in LADA patients.
What LADA Looks and Feels Like
LADA doesn’t have a single physical profile. Two distinct subtypes have been described based on autoantibody levels. People with high antibody levels tend to look more like type 1: leaner body weight, lower insulin production, and faster progression to needing insulin. Those with lower antibody levels more closely resemble type 2 diabetes, with higher body weight and more insulin resistance.
On average, people with LADA have BMI, waist circumference, blood pressure, and triglyceride levels that fall midway between type 1 and type 2 diabetes. Some share lifestyle risk factors with type 2, including excess body weight, larger waist-to-hip ratio, and heavy smoking. But a BMI under 25 is actually one of the screening criteria used to identify LADA in people over 50 who were diagnosed with type 2.
Metabolic syndrome (the cluster of high blood pressure, high blood sugar, excess abdominal fat, and abnormal cholesterol) is more common in LADA than in the general population but less common than in type 2 diabetes. The presence or absence of metabolic syndrome is one practical clue that something other than straightforward type 2 diabetes may be going on.
Why It Gets Misdiagnosed
The most common scenario is straightforward: an adult over 30 develops high blood sugar, and their doctor diagnoses type 2 diabetes. This makes sense on the surface, since type 2 accounts for roughly 90% of diabetes cases in adults. The problem is that standard initial workups don’t include autoantibody testing. Without that test, LADA is invisible.
Certain red flags should prompt further investigation. If you’ve been diagnosed with type 2 diabetes but aren’t overweight, don’t have features of metabolic syndrome, or aren’t responding well to standard oral medications, LADA is worth considering. A personal or family history of other autoimmune conditions (Hashimoto’s thyroiditis, celiac disease, rheumatoid arthritis, Graves’ disease, or pernicious anemia) also raises the likelihood.
The primary diagnostic test is a blood test for GAD65 autoantibodies, which are present in the majority of LADA cases. About 69% of LADA patients test positive for GAD antibodies alone, while roughly 24% have two or more types of autoantibodies. Testing positive for multiple autoantibodies is especially telling: these patients have very high rates of rapid insulin requirement and closely match the clinical and genetic profile of type 1 diabetes.
The Genetic Connection
LADA shares significant genetic overlap with type 1 diabetes. The same immune system genes that increase type 1 risk, specifically certain HLA gene variants involved in how the body distinguishes its own cells from foreign invaders, also increase LADA risk. A large study from Norway found that the majority of high-risk gene combinations for type 1 diabetes were also significant risk factors for LADA, and the same protective gene variants reduced risk for both conditions.
This genetic similarity reinforces the view that LADA is fundamentally an autoimmune process, not a variant of type 2 diabetes. The slower pace of beta cell destruction likely reflects differences in the intensity of the immune attack rather than a completely different disease mechanism.
How LADA Is Managed
The central challenge in managing LADA is preserving whatever beta cell function remains for as long as possible. Since the underlying problem is autoimmune destruction rather than insulin resistance, the treatment approach diverges from standard type 2 management, sometimes significantly.
In studies comparing LADA and type 2 diabetes patients, 62.5% of those with LADA required insulin therapy compared to just 26.7% of those with type 2. Many LADA patients need insulin within the first 18 months after diagnosis, and the proportion increases steadily with disease duration. By the time someone has had LADA for five to ten years, the majority are on insulin.
The question of sulfonylureas (a common class of type 2 medication that pushes the pancreas to produce more insulin) is particularly important. These drugs force already-stressed beta cells to work harder, which may accelerate their destruction in someone with autoimmune-driven damage. This is one of the concrete harms of misdiagnosis: a person with unrecognized LADA may spend years on medications that worsen their long-term outcome.
Early insulin therapy, by contrast, gives the remaining beta cells a rest. Preserving even modest insulin production matters because it makes blood sugar easier to control, reduces the frequency of dangerous lows, and is associated with fewer long-term complications. The goal isn’t to prevent insulin dependence entirely, since the autoimmune process will likely continue, but to slow the decline and maintain more stable blood sugar in the years ahead.
Who Should Be Tested
If you’re an adult with a relatively recent type 2 diabetes diagnosis and any of the following apply, autoantibody testing is reasonable: you’re not overweight, your blood sugar hasn’t responded well to standard medications, you have a personal or family history of autoimmune disease, or you were diagnosed before age 50. The test itself is a simple blood draw for GAD65 antibodies, sometimes combined with other autoantibody panels for greater accuracy.
Getting the right diagnosis changes your treatment plan, your expected disease trajectory, and how aggressively your insulin production should be monitored over time. It also reframes the condition: rather than a lifestyle-related metabolic disorder, LADA is an immune system problem that happens to share surface-level similarities with type 2 diabetes.